Seconds out in fast-melt lawsuit

Related tags Pharmacology Pharmaceutical drug

St Louis, USA-based KV Pharmaceutical says that the US District
Court for the District of Minnesota has denied a motion for a
preliminary injunction by two rival drug delivery companies in a
patent dispute centring on its technology for fast-dissolving oral
drug technology.

While still used in only a minority of oral medicines - with estimated annual sales of $1.7 billion (€1.43bn) in 2002 - fast-melt delivery is experiencing 40 per cent growth a year as companies turn to it to differentiate their products in the marketplace.

The suit was filed against KV and its subsidiary Ethex by CIMA Labs and Schwarz Pharma and sought to make KV cease marketing a fast-melt version of hyoscyamine sulphate, used to treat irritable bowel syndrome, launched by Ethex in January in direct competition to Schwarz' NuLev brand of the drug.

CIMA and Schwarz allege that KV and Ethex infringe CIMA's patented, orally dissolving drug delivery technology called DuraSolv. CIMA licenses a US patent (No 6,024,981) to Schwarz and other companies that wish to sell products that rely on the technology.

The denial of the motion for preliminary injunction allows Ethex to continue marketing the product.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Webinars

Headlines